Ardais Launches Assessment Service Offering for Pharmaceutical Industry.

LEXINGTON, Mass. -- A roadmap to best practices enables consistently high-quality annotated biospecimens for use in translational medicine 

Ardais(R) Corporation, a leading biospecimen solutions provider, today announced the launch of the Adaptive Assessment, a new service offering that uses Ardais' best practices expertise to evaluate biospecimen processes across drug discovery and development efforts at pharmaceutical companies and related service providers.

"Human biospecimens - such as tissue, blood, and serum - are the source of key clinical and molecular information necessary to develop important new therapeutic and diagnostic products," said Donald B. Hawthorne, President and CEO of Ardais Corporation. "Yet, the quality of such information can be adversely affected by the often invisible physical quality problems and data quality problems associated with biospecimens. Our Adaptive Assessment service offering provides each client with a best practices roadmap designed to maximize the value of their important biospecimen assets."

If left unaddressed, these physical quality and data quality problems turn biospecimens into an unreliable resource for research and clinical development programs. Physical quality problems arise from inconsistent collection, management and distribution practices across multiple sites, leading to uncertainty about whether only the biological variability of the biospecimens is being measured. Data quality problems result when biospecimen-related data arrive from multiple sources and in multiple formats, making it difficult to harmonize relevant data and turn such data into valuable information for decision-making.

"This rapidly delivered service offering provides insights to pharmaceutical companies and related service providers about their biospecimen practices. It is made possible by our best practices expertise in the standardization of biospecimen-related physical workflows and structured clinical data annotation developed over the last five years," said Cathy Counsell, Director of Services. "The Adaptive Assessment is tailored to the client's needs and completed in several weeks. It identifies opportunities to increase productivity by optimizing business processes while maintaining regulatory compliance in the collection, annotation, management, and distribution of biospecimens."

About Ardais Corporation

Ardais Corporation addresses all of the challenges of biospecimen management, allowing researchers to focus solely on the research discoveries and clinical developments that will advance translational medicine. As a pioneer in best practices for this field, Ardais offers a software products and services solution that permits academic and commercial scientists and clinicians to standardize and organize their collection, annotation, management, and distribution of biospecimens, thereby enhancing and accelerating research and clinical development. For more information, visit: www.ardais.com.